Mamby C C, Love R R, Feyzi J M
Cancer Prevention Program, University of Wisconsin Comprehensive Cancer Center, Madison.
Breast Cancer Res Treat. 1994;30(3):311-4. doi: 10.1007/BF00665973.
Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects associated with tamoxifen therapy we evaluated changes in protein S and C activity levels in 58 postmenopausal women with surgically resected breast cancer who were disease-free and participating in a double-blind, placebo-controlled, randomized toxicity study of tamoxifen. The changes in protein C activities for the tamoxifen group (mean level = 113%) compared to those in the placebo group (mean level = 115%) were not significant (p = 0.45). Protein S activity levels increased while protein C activity levels decreased from baseline at 24 months in both tamoxifen and placebo groups. We conclude that the possible thrombophlebitis-promoting effect of tamoxifen in postmenopausal women is unlikely to be explained on the basis of protein S and protein C activity level changes.
枸橼酸他莫昔芬是一种合成抗雌激素药物，在绝经后乳腺癌女性患者中作为辅助治疗用药时可带来生存获益。静脉血栓性静脉炎可能会使他莫昔芬治疗复杂化，发生率约为每800治疗年1例。为探究与他莫昔芬治疗相关的可能促凝血作用，我们评估了58例接受手术切除且无疾病的绝经后乳腺癌女性患者的蛋白S和蛋白C活性水平变化，这些患者参与了一项他莫昔芬的双盲、安慰剂对照、随机毒性研究。他莫昔芬组的蛋白C活性变化（平均水平 = 113%）与安慰剂组（平均水平 = 115%）相比无显著差异（p = 0.45）。在他莫昔芬组和安慰剂组中，24个月时蛋白S活性水平均从基线升高，而蛋白C活性水平均从基线降低。我们得出结论，他莫昔芬在绝经后女性中可能的促血栓性静脉炎作用不太可能基于蛋白S和蛋白C活性水平变化来解释。
